AC Immune SA (ACIU)
2.14
-0.12
(-5.31%)
USD |
NASDAQ |
Nov 12, 16:00
2.14
0.00 (0.00%)
Pre-Market: 20:00
AC Immune Enterprise Value : 111.10M for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 111.10M |
| November 11, 2026 | 122.03M |
| November 10, 2026 | 124.76M |
| November 09, 2026 | 138.43M |
| November 06, 2026 | 119.30M |
| November 05, 2026 | 108.36M |
| November 04, 2026 | 124.76M |
| November 03, 2026 | 106.54M |
| November 02, 2026 | 103.81M |
| October 30, 2026 | 118.39M |
| October 29, 2026 | 132.05M |
| October 28, 2026 | 132.05M |
| October 27, 2026 | 121.12M |
| October 26, 2026 | 126.58M |
| October 23, 2026 | 136.61M |
| October 22, 2026 | 143.89M |
| October 21, 2026 | 141.16M |
| October 20, 2026 | 142.98M |
| October 19, 2026 | 137.97M |
| October 16, 2026 | 133.87M |
| October 15, 2026 | 139.34M |
| October 14, 2026 | 134.78M |
| October 13, 2026 | 134.78M |
| October 12, 2026 | 139.34M |
| October 09, 2026 | 143.89M |
| Date | Value |
|---|---|
| October 08, 2026 | 148.45M |
| October 07, 2026 | 150.27M |
| October 06, 2026 | 145.72M |
| October 05, 2026 | 163.02M |
| October 02, 2026 | 164.39M |
| October 01, 2026 | 172.13M |
| September 30, 2026 | 154.83M |
| September 29, 2026 | 148.52M |
| September 28, 2026 | 149.44M |
| September 25, 2026 | 141.24M |
| September 24, 2026 | 153.99M |
| September 23, 2026 | 169.48M |
| September 22, 2026 | 160.37M |
| September 21, 2026 | 153.53M |
| September 18, 2026 | 151.26M |
| September 17, 2026 | 155.81M |
| September 16, 2026 | 153.08M |
| September 15, 2026 | 155.81M |
| September 14, 2026 | 153.99M |
| September 11, 2026 | 163.10M |
| September 10, 2026 | 156.72M |
| September 09, 2026 | 163.10M |
| September 08, 2026 | 164.92M |
| September 04, 2026 | 172.21M |
| September 03, 2026 | 178.59M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Precigen, Inc. | 1.723B |
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| Aldeyra Therapeutics, Inc. | -2.486M |
| BeOne Medicines Ltd. | 40.00B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -10.77M |
| Revenue (Quarterly) | 3.994M |
| Total Expenses (Quarterly) | 14.77M |
| EPS Diluted (Quarterly) | -0.16 |
| Profit Margin (Quarterly) | -269.7% |
| Earnings Yield | -24.28% |